Herbal Supplement Prosta-OK® Neo as an Adjunct Therapy in Patients With Mild to Severe Non-neurogenic Male Lower Urinary Tract Symptoms Receiving Tamsulosin Therapy

Inclusion Criteria:

• male between the ages of 30 and 55 when signing the informed consent form

• the subject was diagnosed with mild to severe non-neurogenic lower urinary tractsymptoms and planed to receive Tamsulosin therapy

• the sum of International Prostate Symptom Score (IPSS) on questions 1 to 7 was 10points or higher

• the subject can take medication via oral or nasogastric tube confirmed with thefunction of absorption by the principal investigator or co-principal investigators

• the subject was willing to corporate study-related procedures and sign the informedconsent form

Exclusion Criteria:

• post-void residual urine volume greater than 200 mL or peak of maximum urine flow rateless than 5 mL/s

• total serum prostate-specific antigen higher than 10 ng/mL

• bladder outlet obstruction caused by reasons other than benign prostatic hyperplasia

• lower urinary tract symptoms caused by neurological disease such as CerebrovascularDiseases, Parkinson's, dementia, Multiple Sclerosis (MS), spinal cord injuries (SCI),cauda equina syndrome, and Peripheral Neuropathy

• history or evidence of prostate cancer, male reproductive cancers, bladder cancer, andcancer of the ureter and urethra

• history or evidence of acute urinary retention (AUR)

• history or evidence of acute orthostatic hypotension

• with the urinary catheter or intermittent catheter

• stone in the urinary system

• Interstitial cystitis (IC), neurogenic bladder, overactive bladder (OAB) andInflammatory Bowel Disease (IBD) within 3 mo prior to study entry

• chemotherapy or radiation therapy within 3 mo prior to study entry

• immunosuppressive therapy within 2 mo prior to study entry

• pelvic surgery or urinary surgery within 2 mo prior to study entry

• 5-alpha-reductase inhibitors use within 6 mo prior to entry or alpha-1-adrenergicblockers use within 2 w prior to entry

• the subject plans to use medication other than Tamsulosin such as alpha-blocker, 5-alpha-reductase inhibitors, antimuscarinic drugs, phosphodiesterase type 5 inhibitor (PDE5 inhibitors), Beta-3 agonists, desmopressin, diuretics, phenazopyridine, otherdrugs or foods are known to interact with tamsulosin and steroid or a nonsteroidalanti-inflammatory drug during participating in the study.

• the subject plans to receive cataract surgery during participating in the study or 1mo after participating in the study.

• the subject took other therapies such as acupuncture or phytotherapy, including SawPalmetto, Pygeum Africanum, Hypoxis Rooperi, Rye-pollen extract, and Pumpkin Seedextract within 2 w prior to entry.

• the subject took Chinese herbs such as Soaring Dragon Decoction, Rehmannia RightFormula, Powder for Five Types of Painful Urinary Dysfunction, Minor BupleurumDecoction, Artemisiae Scopariae Decoction, Decoction to Enrich Yin and Direct FireDownward, Tonifies Qi、Coptis Decoction to Relieve Toxicity and related modifications,Radix Rehmanniae, Cortex Moutan, Radix Pulsatillae, Herba Taraxaci, Herba Portulacae,Fructus Forsythiae, Flos Lonicerae, Herba Lophatheri, Fructus Gardeniae, Phellinuslinteus within 7 days prior to entry.

• have a history of allergy to the ingredients of investigational product

• Serum Glutamic-Oxaloacetic Transaminase and serum Glutamic-Pyruvic Transaminase weremore than three times of normal range or Serum creatinine less than 1.5 mg/dL

• have a history of substance abuse within 2 yr prior to entry

• participating in any clinical trial such as health food, herbal extracts, and drugwithin 30 days prior to entry

• have other significant diseases and confirmed by the principal investigator asnon-eligible to be enrolled in the study